Figure 1

Results of the gene chip microarray analysis and validation. (A) Visual display of the cluster analysis for the BCL11B siRNA935-transfected and control cells. (B) Principal component analysis. The closer the dots, the more similar the gene expression profiles are; the farther apart the dots, the greater the differences are. (C) Two-dimensional scatterplot analysis of gene expression values for all genes on the BCL11B siRNA935-transfected cells and control cells from the microarray. Yellow dots represent genes absent from both samples; blue dots represent genes present in one sample but absent from the other sample; and red dots represent genes present in both samples. Dots outside the 2 × difference lines, indicated by black arrows, represent differentially expressed genes. The farther from the line, the greater the difference in gene expression are. (D) Analysis of pathways closely related to tumor cell proliferation and apoptosis. Results are shown as fold-change in mRNA transcripts. Genes indicated with a red star are in the apoptosis pathway; genes indicated with a blue star are in the transforming growth factor-β pathway. (E) Gene validation by real-time PCR. Changes in TNFSF 10, BCL2L 1, and SPP 1 expression levels agreed with the microarray results, while those of CREBBP did not. (F) Reduced BCL-2 protein expression was confirmed by flow cytometry. BCL-2 expression in BCL11B siRNA3-transfected cells was significantly lower, at 46% of that in SC (99.1%), MOCK (99.2%), and NC cells (99.7%).